Literature DB >> 34187629

Psychological burden of COVID-19 on mild and moderate chronic spontaneous urticarial.

Sengul Beyaz1, Semra Demir1, Nida Oztop1, Pelin Karadag1, Raif Coskun2, Bahauddin Colakoglu1, Suna Buyukozturk1, Asli Gelincik1.   

Abstract

Background: The impact of coronavirus disease 2019 (COVID-19) related mental health status on chronic spontaneous urticaria (CSU) has not been addressed before. Objective: The aim of this study was to evaluate the depression, anxiety and stress levels, and the fear of COVID-19 in patients with mild-to-moderate CSU and to determine their impact on urticaria activity during the pandemic.
Methods: A total of 509 patients with mild-to-moderate CSU were prospectively evaluated with validated scales, the Depression Anxiety Stress Scale 21 (DASS-21) and the Fear of COVID-19 Scale (FCV-19S) during the lockdown period (LP) and the return to normal period (RTNP). CSU activity was determined with the urticaria activity score summed over 7 days (UAS7) and medication scores (MS). UAS7 and MS before the pandemic were retrospectively collected from medical records.
Results: The median UAS7 and MS were both significantly higher in the LP than in the median of related scores during the prepandemic period (p < 0.0001) and the RTNP (p < 0.0001). The mean FCV-19S and DASS-21 scores were both significantly higher in the LP than in the RTNP (p < 0.0001). The FCV-19S and the DASS-21 anxiety and stress subscales were significantly higher in women. The UAS7s were positively correlated with the FCV-19S and depression, anxiety, and stress subscale scores.
Conclusion: Fear of COVID-19, anxiety, depression, and stress during the COVID-19 pandemic, especially when strict isolation measures are taken, have a significant impact on mental health and urticaria activity in patients with mild-to-moderate CSU, even though they are not infected. Psychological support for patients with CSU seems to be important to control disease activity during the pandemic.

Entities:  

Year:  2021        PMID: 34187629     DOI: 10.2500/aap.2021.42.210026

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  5 in total

1.  Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2.

Authors:  Eli Magen; Avi Yakov; Ilan Green; Ariel Israel; Shlomo Vinker; Eugene Merzon
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

2.  Eosinophilic esophagitis: from discovery to effective treatment.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-05-01       Impact factor: 2.873

3.  SARS-CoV-2 infection and the human immune system: A continuing journey of discovery.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-11-01       Impact factor: 2.587

4.  Vaccine preventable diseases, vaccine hesitancy, and COVID-19: A role for the allergist/immunologist.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-09-01       Impact factor: 2.587

5.  The COVID-19 Pandemic Affects Male Patients With Chronic Spontaneous Urticaria More Than Female Patients.

Authors:  Huzeyfe Kulu; Mustafa Atasoy; Kemal Özyurt; Marcus Maurer; Atıl Avcı; Muhammet Reşat Akkuş; Ragıp Ertaş
Journal:  Front Immunol       Date:  2021-10-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.